Source:http://linkedlifedata.com/resource/pubmed/id/15050982
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-3-30
|
pubmed:abstractText |
Introduction of specific cyclooxygenase (COX)-2 inhibitors holds the promise of improved treatment for inflammatory processes without the gastrointestinal effects associated with the conventional non-selective nonsteroidal anti-inflammatory drugs (NS-NSAID), which inhibit both COX-1 and COX-2 activity. Dysmenorrhea is a common inflammatory process that affects many adolescent girls, and is the leading cause of recurrent short-term school or work absenteeism among female adolescents and young adults. In vitro studies have shown that the selective COX-2 inhibitors have a potent tocolytic effect. In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. Adolescents suffering from dysmenorrhea with a prior history of peptic ulcer, or with a history of NS-NSAID gastrointestinal adverse effects, or who require high doses of NS-NSAID during the menstrual period, as well as adolescents with coagulation deficiencies, may benefit from the use of a specific COX-2 inhibitor. Studies are warranted to explore whether the specific COX-2 inhibitors are effective in treating dysmenorrhea in the adolescent age group.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1083-3188
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
75-9
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15050982-Adolescent,
pubmed-meshheading:15050982-Adult,
pubmed-meshheading:15050982-Animals,
pubmed-meshheading:15050982-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:15050982-Cyclooxygenase 2,
pubmed-meshheading:15050982-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:15050982-Cyclooxygenase Inhibitors,
pubmed-meshheading:15050982-Dysmenorrhea,
pubmed-meshheading:15050982-Female,
pubmed-meshheading:15050982-Humans,
pubmed-meshheading:15050982-Isoenzymes,
pubmed-meshheading:15050982-Membrane Proteins,
pubmed-meshheading:15050982-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:15050982-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
|
pubmed:affiliation |
Hasbro Children's Hospital, and Department of Pediatrics, Brown University, Providence, Rhode Island 02903, USA. ZHarel@Lifespan.org
|
pubmed:publicationType |
Journal Article,
Review
|